Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab tirumotecan + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Sacituzumab tirumotecan + paclitaxel** is a combination investigational therapy being studied primarily for advanced and metastatic solid tumors, such as HER2-negative gastric/gastroesophageal junction/esophageal adenocarcinoma. The combination consists of an antibody-drug conjugate (ADC), sacituzumab tirumotecan, and the chemotherapeutic agent paclitaxel. Sacituzumab tirumotecan targets TROP2 (trophoblast cell surface antigen 2) with a humanized anti-TROP2 monoclonal antibody linked by a novel hydrolyzable, pH-sensitive linker to a belotecan-derivative topoisomerase I inhibitor (payload), aiming to deliver cytotoxic agents specifically to cells overexpressing TROP2 and induce DNA damage and apoptosis. Paclitaxel stabilizes microtubules, inhibiting cell division. The combination is designed to increase anti-tumor efficacy via complementary mechanisms: targeted DNA damage and mitotic inhibition[1][7].
- Other names
- sacituzumab tirumotecan plus paclitaxel
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on sacituzumab tirumotecan + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab tirumotecan + paclitaxel.